|
Tacabrutideg Clinical Trials
6 actively recruiting trials across 4 locations
▲ +1 trial since September 2026
Also known as: BGB-16673
Pipeline
Phase 2: 1Phase 3: 2Phase 1/2: 3
Top Sponsors
- BeOne Medicines5
- Massachusetts General Hospital1
Indications
- Cancer6
- Chronic Lymphocytic Leukemia4
- B-cell Malignancy3
- Waldenström Macroglobulinemia2
- Small Lymphocytic Lymphoma2
Birmingham, Alabama2 trials
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
University of Alabama At Birmingham Hospital
Phase 1/2
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
University of Alabama At Birmingham Hospital
Phase 3
Other1 trial
Phoenix, Arizona1 trial
Jonesboro, Arkansas1 trial
Boston, Massachusetts1 trial
Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL
Massachusetts General Hospital
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.